CA2965895A1 — The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
Assigned to Indivior UK Ltd · Expires 2016-05-12 · 10y expired
What this patent protects
The disclosure provides a use of buprenorphine for treating opioid dependence or pain in a human in need thereof comprising: (a) use of a first injectable composition comprising from 280 mg to 320 mg of buprenorphine once per month for two months; and (b) use of a second injectab…
USPTO Abstract
The disclosure provides a use of buprenorphine for treating opioid dependence or pain in a human in need thereof comprising: (a) use of a first injectable composition comprising from 280 mg to 320 mg of buprenorphine once per month for two months; and (b) use of a second injectable composition comprising from 80 mg to 120 mg of buprenorphine once per month beginning with the third month, and for each month thereafter. The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.
Drugs covered by this patent
- Subutex (BUPRENORPHINE) · Purdue Pharma Lp
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.